FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Front Vet Sci / Treatment Effects of Intra-Articular Allogenic Mesenchymal S...
Frontiers in veterinary science2022; 9; 907616; doi: 10.3389/fvets.2022.907616

Treatment Effects of Intra-Articular Allogenic Mesenchymal Stem Cell Secretome in an Equine Model of Joint Inflammation.

Abstract: Allogenic mesenchymal stem cell (MSC) secretome is a novel intra-articular therapeutic that has shown promise in and small animal models and warrants further investigation. Unassigned: To investigate if intra-articular allogenic MSC-secretome has anti-inflammatory effects using an equine model of joint inflammation. Unassigned: Randomized positively and negatively controlled experimental study. Unassigned: In phase 1, joint inflammation was induced bilaterally in radiocarpal joints of eight horses by injecting 0.25 ng lipopolysaccharide (LPS). After 2 h, the secretome of INFy and TNFα stimulated allogeneic equine MSCs was injected in one randomly assigned joint, while the contralateral joint was injected with medium (negative control). Clinical parameters (composite welfare scores, joint effusion, joint circumference) were recorded, and synovial fluid samples were analyzed for biomarkers (total protein, WBCC; eicosanoid mediators, CCL2; TNFα; MMP; GAGs; C2C; CPII) at fixed post-injection hours (PIH 0, 8, 24, 72, and 168 h). The effects of time and treatment on clinical and synovial fluid parameters and the presence of time-treatment interactions were evaluated. For phase 2, allogeneic MSC-secretome vs. allogeneic equine MSCs (positive control) was tested using a similar methodology. Unassigned: In phase 1, the joint circumference was significantly ( < 0.05) lower in the MSC-secretome treated group compared to the medium control group at PIH 24, and significantly higher peak synovial GAG values were noted at PIH 24 ( < 0.001). In phase 2, no significant differences were noted between the treatment effects of MSC-secretome and MSCs. Unassigned: This study is a controlled experimental study and therefore cannot fully reflect natural joint disease. In phase 2, two therapeutics are directly compared and there is no negative control. Unassigned: In this model of joint inflammation, intra-articular MSC-secretome injection had some clinical anti-inflammatory effects. An effect on cartilage metabolism, evident as a rise in GAG levels was also noted, although it is unclear whether this could be considered a beneficial or detrimental effect. When directly comparing MSC-secretome to MSCs in this model results were comparable, indicating that MSC-secretome could be a viable off-the-shelf alternative to MSC treatment.
Copyright © 2022 Kearney, Khatab, van Buul, Plomp, Korthagen, Labberté, Goodrich, Kisiday, Van Weeren, van Osch and Brama.
Get Full Text
Publication Date: 2022-06-22 PubMed ID: 35812845PubMed Central: PMC9257274DOI: 10.3389/fvets.2022.907616Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article titled ‘Treatment Effects of Intra-Articular Allogenic Mesenchymal Stem Cell Secretome in an Equine Model of Joint Inflammation’ investigates the therapeutic effects of injecting mesenchymal stem cell (MSC) secretome into the joints of inflamed horse models.

Objective and Methodology

During the investigation, the goal was to determine whether the secretions of mesenchymal stem cells (MSCs) had an anti-inflammatory effect on equine joint inflammation. There were two phases in the study. In the first, inflammation was induced in the radiocarpal joints of eight horses by injecting lipopolysaccharide (LPS). Two hours later, one joint was randomly selected and treated with allogeneic equine MSCs’ secretome, while a medium was injected into the opposite joint as a negative control. The second phase involved comparing the anti-inflammatory effects of the MSCs’ secretome with that of allogeneic equine MSCs.

  • Clinical parameters including composite welfare scores, joint effusion, and joint circumference, were recorded.
  • Synovial fluid samples were analysed for the presence of various biomarkers at fixed intervals which were post-injection hours (PIH) 0, 8, 24, 72, and 168 hours.
  • The effects of time and treatment on metabolism and inflammation were studied and any time-treatment interactions were recorded.

Findings

During the first phase of the study, the researchers noticed a significant decrease in joint circumference in the group treated with MSC’s secretome compared to the control group. They also found an increase in synovial GAG values at PIH 24. In contrast, no marked differences in treatment effects between transmission of MSC-secretome and MSCs were discovered during the second phase.

Limitations

The primary limitations of the study were its controlled experimental nature, which can’t accurately mirror natural joint disease. Additionally, during the second phase, there was a direct comparison of two remedial interventions without a negative control.

Conclusion

The MSC-secretome injection appeared to have some anti-inflammatory effect on joint inflammation. This treatment also affected the joint’s cartilage metabolism, as indicated by a rise in synovial GAG levels. Nevertheless, the researchers are uncertain whether this could be considered a beneficial or detrimental effect. The results suggested that MSC-secretome could be a feasible substitute for MSC treatment as their effects on inflammation were comparable.

Cite This Article

APA
Kearney CM, Khatab S, van Buul GM, Plomp SGM, Korthagen NM, Labberté MC, Goodrich LR, Kisiday JD, Van Weeren PR, van Osch GJVM, Brama PAJ. (2022). Treatment Effects of Intra-Articular Allogenic Mesenchymal Stem Cell Secretome in an Equine Model of Joint Inflammation. Front Vet Sci, 9, 907616. https://doi.org/10.3389/fvets.2022.907616

Publication

Frontiers in veterinary science
ISSN: 2297-1769
NlmUniqueID: 101666658
Country: Switzerland
Language: English
Volume: 9
Pages: 907616
PII: 907616

Researcher Affiliations

Kearney, Clodagh M
  • School of Veterinary Medicine, University College Dublin, Dublin, Ireland.
Khatab, Sohrab
  • Department of Orthopaedics and Sports Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
van Buul, Gerben M
  • Department of Orthopaedics and Sports Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
  • Beacon Hospital, Dublin, Ireland.
Plomp, Saskia G M
  • Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands.
Korthagen, Nicoline M
  • Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands.
Labberté, Margot C
  • School of Veterinary Medicine, University College Dublin, Dublin, Ireland.
Goodrich, Laurie R
  • Equine Orthopaedic Research Center, Colorado State University, Fort Collins, CO, United States.
Kisiday, John D
  • Equine Orthopaedic Research Center, Colorado State University, Fort Collins, CO, United States.
Van Weeren, P R
  • Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, Netherlands.
van Osch, Gerjo J V M
  • Department of Orthopaedics and Sports Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
  • Department of Otorhinolaryngology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
Brama, Pieter A J
  • School of Veterinary Medicine, University College Dublin, Dublin, Ireland.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

This article includes 64 references
  1. McIlwraith CW, Frisbie DD, Kawcak CE. The horse as a model of naturally occurring osteoarthritis.. Bone Joint Res 2012 Nov;1(11):297-309.
    doi: 10.1302/2046-3758.111.2000132pmc: PMC3626203pubmed: 23610661google scholar: lookup
  2. Colbath AC, Dow SW, McIlwraith CW, Goodrich LR. Mesenchymal stem cells for treatment of musculoskeletal disease in horses: Relative merits of allogeneic versus autologous stem cells.. Equine Vet J 2020 Sep;52(5):654-663.
    doi: 10.1111/evj.13233pubmed: 31971273google scholar: lookup
  3. Colbath AC, Dow SW, Hopkins LS, Phillips JN, McIlwraith CW, Goodrich LR. Single and repeated intra-articular injections in the tarsocrural joint with allogeneic and autologous equine bone marrow-derived mesenchymal stem cells are safe, but did not reduce acute inflammation in an experimental interleukin-1β model of synovitis.. Equine Vet J 2020 Jul;52(4):601-612.
    doi: 10.1111/evj.13222pmc: PMC7283005pubmed: 31821594google scholar: lookup
  4. EMA. First Stem Cell-Based Veterinary Medicine Recommended for Marketing Authorisation. .
  5. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators.. J Cell Biochem 2006 Aug 1;98(5):1076-84.
    doi: 10.1002/jcb.20886pubmed: 16619257google scholar: lookup
  6. Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, Fuchs S, Epstein SE. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms.. Circulation 2004 Mar 30;109(12):1543-9.
    doi: 10.1161/01.CIR.0000124062.31102.57pubmed: 15023891google scholar: lookup
  7. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide.. Cell Stem Cell 2008 Feb 7;2(2):141-50.
    doi: 10.1016/j.stem.2007.11.014pubmed: 18371435google scholar: lookup
  8. Prockop DJ. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms.. Mol Ther 2009 Jun;17(6):939-46.
    doi: 10.1038/mt.2009.62pmc: PMC2835176pubmed: 19337235google scholar: lookup
  9. Timmers L, Lim SK, Hoefer IE, Arslan F, Lai RC, van Oorschot AA, Goumans MJ, Strijder C, Sze SK, Choo A, Piek JJ, Doevendans PA, Pasterkamp G, de Kleijn DP. Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction.. Stem Cell Res 2011 May;6(3):206-14.
    doi: 10.1016/j.scr.2011.01.001pubmed: 21419744google scholar: lookup
  10. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system.. Nat Rev Immunol 2012 Apr 25;12(5):383-96.
    doi: 10.1038/nri3209pubmed: 22531326google scholar: lookup
  11. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, Noiseux N, Zhang L, Pratt RE, Ingwall JS, Dzau VJ. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells.. Nat Med 2005 Apr;11(4):367-8.
    doi: 10.1038/nm0405-367pubmed: 15812508google scholar: lookup
  12. Murphy JM, Fink DJ, Hunziker EB, Barry FP. Stem cell therapy in a caprine model of osteoarthritis.. Arthritis Rheum 2003 Dec;48(12):3464-74.
    doi: 10.1002/art.11365pubmed: 14673997google scholar: lookup
  13. Barry F, Murphy M. Mesenchymal stem cells in joint disease and repair.. Nat Rev Rheumatol 2013 Oct;9(10):584-94.
    doi: 10.1038/nrrheum.2013.109pubmed: 23881068google scholar: lookup
  14. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation.. Mol Ther 2012 Jan;20(1):14-20.
    doi: 10.1038/mt.2011.211pmc: PMC3255583pubmed: 22008910google scholar: lookup
  15. van Buul GM, Villafuertes E, Bos PK, Waarsing JH, Kops N, Narcisi R, Weinans H, Verhaar JA, Bernsen MR, van Osch GJ. Mesenchymal stem cells secrete factors that inhibit inflammatory processes in short-term osteoarthritic synovium and cartilage explant culture.. Osteoarthritis Cartilage 2012 Oct;20(10):1186-96.
    doi: 10.1016/j.joca.2012.06.003pubmed: 22771777google scholar: lookup
  16. Platas J, Guillén MI, del Caz MD, Gomar F, Mirabet V, Alcaraz MJ. Conditioned media from adipose-tissue-derived mesenchymal stem cells downregulate degradative mediators induced by interleukin-1β in osteoarthritic chondrocytes.. Mediators Inflamm 2013;2013:357014.
    doi: 10.1155/2013/357014pmc: PMC3864089pubmed: 24363499google scholar: lookup
  17. Khatab S, van Osch GJ, Kops N, Bastiaansen-Jenniskens YM, Bos PK, Verhaar JA, Bernsen MR, van Buul GM. Mesenchymal stem cell secretome reduces pain and prevents cartilage damage in a murine osteoarthritis model.. Eur Cell Mater 2018 Nov 6;36:218-230.
    doi: 10.22203/eCM.v036a16pubmed: 30398288google scholar: lookup
  18. Mocchi M, Dotti S, Bue MD, Villa R, Bari E, Perteghella S, Torre ML, Grolli S. Veterinary Regenerative Medicine for Musculoskeletal Disorders: Can Mesenchymal Stem/Stromal Cells and Their Secretome Be the New Frontier?. Cells 2020 Jun 11;9(6).
    doi: 10.3390/cells9061453pmc: PMC7349187pubmed: 32545382google scholar: lookup
  19. Bussche L, Harman RM, Syracuse BA, Plante EL, Lu YC, Curtis TM, Ma M, Van de Walle GR. Microencapsulated equine mesenchymal stromal cells promote cutaneous wound healing in vitro.. Stem Cell Res Ther 2015 Apr 11;6(1):66.
    doi: 10.1186/s13287-015-0037-xpmc: PMC4413990pubmed: 25889766google scholar: lookup
  20. Marx C, Gardner S, Harman RM, Van de Walle GR. The mesenchymal stromal cell secretome impairs methicillin-resistant Staphylococcus aureus biofilms via cysteine protease activity in the equine model.. Stem Cells Transl Med 2020 Jul;9(7):746-757.
    doi: 10.1002/sctm.19-0333pmc: PMC7308642pubmed: 32216094google scholar: lookup
  21. Lange-Consiglio A, Rossi D, Tassan S, Perego R, Cremonesi F, Parolini O. Conditioned medium from horse amniotic membrane-derived multipotent progenitor cells: immunomodulatory activity in vitro and first clinical application in tendon and ligament injuries in vivo.. Stem Cells Dev 2013 Nov 15;22(22):3015-24.
    doi: 10.1089/scd.2013.0214pubmed: 23795963google scholar: lookup
  22. Kearney CM, Korthagen NM, Plomp SGM, Labberté MC, de Grauw JC, van Weeren PR, Brama PAJ. Treatment effects of intra-articular triamcinolone acetonide in an equine model of recurrent joint inflammation.. Equine Vet J 2021 Nov;53(6):1277-1286.
    doi: 10.1111/evj.13396pubmed: 33280164google scholar: lookup
  23. Kisiday JD, Hale BW, Almodovar JL, Lee CM, Kipper MJ, Wayne McIlwraith C, Frisbie DD. Expansion of mesenchymal stem cells on fibrinogen-rich protein surfaces derived from blood plasma.. J Tissue Eng Regen Med 2011 Aug;5(8):600-11.
    doi: 10.1002/term.352pubmed: 21774083google scholar: lookup
  24. Guest DJ, Dudhia J, Smith RKW, Roberts SJ, Conzemius M, Innes JF, Fortier LA, Meeson RL. Position Statement: Minimal Criteria for Reporting Veterinary and Animal Medicine Research for Mesenchymal Stromal/Stem Cells in Orthopedic Applications.. Front Vet Sci 2022;9:817041.
    doi: 10.3389/fvets.2022.817041pmc: PMC8936138pubmed: 35321059google scholar: lookup
  25. Kisiday JD, Goodrich LR, McIlwraith CW, Frisbie DD. Effects of equine bone marrow aspirate volume on isolation, proliferation, and differentiation potential of mesenchymal stem cells.. Am J Vet Res 2013 May;74(5):801-7.
    doi: 10.2460/ajvr.74.5.801pubmed: 23627395google scholar: lookup
  26. Kisiday JD, Colbath AC, Tangtrongsup S. Effect of culture duration on chondrogenic preconditioning of equine bone marrow mesenchymal stem cells in self-assembling peptide hydrogel.. J Orthop Res 2019 Jun;37(6):1368-1375.
    doi: 10.1002/jor.24123pubmed: 30095195google scholar: lookup
  27. Kisiday JD, Kopesky PW, Evans CH, Grodzinsky AJ, McIlwraith CW, Frisbie DD. Evaluation of adult equine bone marrow- and adipose-derived progenitor cell chondrogenesis in hydrogel cultures.. J Orthop Res 2008 Mar;26(3):322-31.
    doi: 10.1002/jor.20508pubmed: 17960654google scholar: lookup
  28. Colbath AC, Dow SW, Phillips JN, McIlwraith CW, Goodrich LR. Autologous and Allogeneic Equine Mesenchymal Stem Cells Exhibit Equivalent Immunomodulatory Properties In Vitro.. Stem Cells Dev 2017 Apr 1;26(7):503-511.
    doi: 10.1089/scd.2016.0266pubmed: 27958776google scholar: lookup
  29. Owens JG, Kamerling SG, Stanton SR, Keowen ML, Prescott-Mathews JS. Effects of pretreatment with ketoprofen and phenylbutazone on experimentally induced synovitis in horses.. Am J Vet Res 1996 Jun;57(6):866-74.
    pubmed: 8725815
  30. de Grauw JC, van de Lest CH, van Weeren PR. A targeted lipidomics approach to the study of eicosanoid release in synovial joints.. Arthritis Res Ther 2011 Jul 27;13(4):R123.
    doi: 10.1186/ar3427pmc: PMC3239362pubmed: 21794148google scholar: lookup
  31. de Grauw JC, van de Lest CH, Brama PA, Rambags BP, van Weeren PR. In vivo effects of meloxicam on inflammatory mediators, MMP activity and cartilage biomarkers in equine joints with acute synovitis.. Equine Vet J 2009 Sep;41(7):693-9.
    doi: 10.2746/042516409X436286pubmed: 19927589google scholar: lookup
  32. Cokelaere SM, Plomp SGM, de Boef E, de Leeuw M, Bool S, van de Lest CHA, van Weeren PR, Korthagen NM. Sustained intra-articular release of celecoxib in an equine repeated LPS synovitis model.. Eur J Pharm Biopharm 2018 Jul;128:327-336.
    doi: 10.1016/j.ejpb.2018.05.001pubmed: 29729412google scholar: lookup
  33. de Grauw JC, Brama PA, Wiemer P, Brommer H, van de Lest CH, van Weeren PR. Cartilage-derived biomarkers and lipid mediators of inflammation in horses with osteochondritis dissecans of the distal intermediate ridge of the tibia.. Am J Vet Res 2006 Jul;67(7):1156-62.
    doi: 10.2460/ajvr.67.7.1156pubmed: 16817736google scholar: lookup
  34. de Grauw JC, van Loon JP, van de Lest CH, Brunott A, van Weeren PR. In vivo effects of phenylbutazone on inflammation and cartilage-derived biomarkers in equine joints with acute synovitis.. Vet J 2014 Jul;201(1):51-6.
    doi: 10.1016/j.tvjl.2014.03.030pubmed: 24888681google scholar: lookup
  35. Sladek S, Kearney C, Crean D, Brama PAJ, Tajber L, Fawcett K, Labberte MC, Leggett B, Brayden DJ. Intra-articular delivery of a nanocomplex comprising salmon calcitonin, hyaluronic acid, and chitosan using an equine model of joint inflammation.. Drug Deliv Transl Res 2018 Oct;8(5):1421-1435.
    doi: 10.1007/s13346-018-0557-xpubmed: 29947020google scholar: lookup
  36. Toh WS, Foldager CB, Pei M, Hui JH. Advances in mesenchymal stem cell-based strategies for cartilage repair and regeneration.. Stem Cell Rev Rep 2014 Oct;10(5):686-96.
    doi: 10.1007/s12015-014-9526-zpubmed: 24869958google scholar: lookup
  37. Zhang J, Huang X, Wang H, Liu X, Zhang T, Wang Y, Hu D. The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy.. Stem Cell Res Ther 2015 Dec 1;6:234.
    doi: 10.1186/s13287-015-0240-9pmc: PMC4665863pubmed: 26620426google scholar: lookup
  38. Frisbie DD, Kawcak CE, Trotter GW, Powers BE, Walton RM, McIlwraith CW. Effects of triamcinolone acetonide on an in vivo equine osteochondral fragment exercise model.. Equine Vet J 1997 Sep;29(5):349-59.
    doi: 10.1111/j.2042-3306.1997.tb03138.xpubmed: 9306060google scholar: lookup
  39. Céleste C, Ionescu M, Robin Poole A, Laverty S. Repeated intraarticular injections of triamcinolone acetonide alter cartilage matrix metabolism measured by biomarkers in synovial fluid.. J Orthop Res 2005 May;23(3):602-10.
    doi: 10.1016/j.orthres.2004.10.003pubmed: 15885481google scholar: lookup
  40. McIlwraith CW. Use of synovial fluid and serum biomarkers in equine bone and joint disease: a review.. Equine Vet J 2005 Sep;37(5):473-82.
    doi: 10.2746/042516405774480102pubmed: 16163952google scholar: lookup
  41. Frisbie DD, Kisiday JD, Kawcak CE, Werpy NM, McIlwraith CW. Evaluation of adipose-derived stromal vascular fraction or bone marrow-derived mesenchymal stem cells for treatment of osteoarthritis.. J Orthop Res 2009 Dec;27(12):1675-80.
    doi: 10.1002/jor.20933pubmed: 19544397google scholar: lookup
  42. Ferris DJ, Frisbie DD, Kisiday JD, McIlwraith CW, Hague BA, Major MD, Schneider RK, Zubrod CJ, Kawcak CE, Goodrich LR. Clinical outcome after intra-articular administration of bone marrow derived mesenchymal stem cells in 33 horses with stifle injury.. Vet Surg 2014 Mar;43(3):255-65.
    doi: 10.1111/j.1532-950X.2014.12100.xpubmed: 24433318google scholar: lookup
  43. Van Loon VJ, Scheffer CJ, Genn HJ, Hoogendoorn AC, Greve JW. Clinical follow-up of horses treated with allogeneic equine mesenchymal stem cells derived from umbilical cord blood for different tendon and ligament disorders.. Vet Q 2014;34(2):92-7.
    doi: 10.1080/01652176.2014.949390pubmed: 25072527google scholar: lookup
  44. Broeckx SY, Seys B, Suls M, Vandenberghe A, Mariën T, Adriaensen E, Declercq J, Van Hecke L, Braun G, Hellmann K, Spaas JH. Equine Allogeneic Chondrogenic Induced Mesenchymal Stem Cells Are an Effective Treatment for Degenerative Joint Disease in Horses.. Stem Cells Dev 2019 Mar 15;28(6):410-422.
    doi: 10.1089/scd.2018.0061pmc: PMC6441287pubmed: 30623737google scholar: lookup
  45. Colbath AC, Dow SW, Hopkins LS, Phillips JN, McIlwraith CW, Goodrich LR. Allogeneic vs. autologous intra-articular mesenchymal stem cell injection within normal horses: Clinical and cytological comparisons suggest safety.. Equine Vet J 2020 Jan;52(1):144-151.
    doi: 10.1111/evj.13136pubmed: 31120574google scholar: lookup
  46. Williams LB, Koenig JB, Black B, Gibson TW, Sharif S, Koch TG. Equine allogeneic umbilical cord blood derived mesenchymal stromal cells reduce synovial fluid nucleated cell count and induce mild self-limiting inflammation when evaluated in an lipopolysaccharide induced synovitis model.. Equine Vet J 2016 Sep;48(5):619-25.
    doi: 10.1111/evj.12477pubmed: 26114736google scholar: lookup
  47. Barrachina L, Remacha AR, Romero A, Vitoria A, Albareda J, Prades M, Roca M, Zaragoza P, Vázquez FJ, Rodellar C. Assessment of effectiveness and safety of repeat administration of proinflammatory primed allogeneic mesenchymal stem cells in an equine model of chemically induced osteoarthritis.. BMC Vet Res 2018 Aug 17;14(1):241.
    doi: 10.1186/s12917-018-1556-3pmc: PMC6098603pubmed: 30119668google scholar: lookup
  48. Carrade DD, Lame MW, Kent MS, Clark KC, Walker NJ, Borjesson DL. Comparative Analysis of the Immunomodulatory Properties of Equine Adult-Derived Mesenchymal Stem Cells().. Cell Med 2012;4(1):1-11.
    doi: 10.3727/215517912X647217pmc: PMC3495591pubmed: 23152950google scholar: lookup
  49. Moran CJ, Ramesh A, Brama PA, O'Byrne JM, O'Brien FJ, Levingstone TJ. The benefits and limitations of animal models for translational research in cartilage repair.. J Exp Orthop 2016 Dec;3(1):1.
    doi: 10.1186/s40634-015-0037-xpmc: PMC4703594pubmed: 26915001google scholar: lookup
  50. Laverty S, Sandy JD, Celeste C, Vachon P, Marier JF, Plaas AH. Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses.. Arthritis Rheum 2005 Jan;52(1):181-91.
    doi: 10.1002/art.20762pubmed: 15641100google scholar: lookup
  51. de Grauw JC, van de Lest CH, van Weeren PR. Inflammatory mediators and cartilage biomarkers in synovial fluid after a single inflammatory insult: a longitudinal experimental study.. Arthritis Res Ther 2009;11(2):R35.
    doi: 10.1186/ar2640pmc: PMC2688180pubmed: 19272138google scholar: lookup
  52. van den Boom R, van de Lest CH, Bull S, Brama RA, van Weeren PR, Barneveld A. Influence of repeated arthrocentesis and exercise on synovial fluid concentrations of nitric oxide, prostaglandin E2 and glycosaminoglycans in healthy equine joints.. Equine Vet J 2005 May;37(3):250-6.
    doi: 10.2746/0425164054530740pubmed: 15892235google scholar: lookup
  53. Orth P, Zurakowski D, Alini M, Cucchiarini M, Madry H. Reduction of sample size requirements by bilateral versus unilateral research designs in animal models for cartilage tissue engineering.. Tissue Eng Part C Methods 2013 Nov;19(11):885-91.
    doi: 10.1089/ten.tec.2012.0699pmc: PMC3793650pubmed: 23510128google scholar: lookup
  54. Dyson S. Can lameness be graded reliably?. Equine Vet J 2011 Jul;43(4):379-82.
    doi: 10.1111/j.2042-3306.2011.00391.xpubmed: 21631579google scholar: lookup
  55. Palmer JL, Bertone AL, Malemud CJ, Mansour J. Biochemical and biomechanical alterations in equine articular cartilage following an experimentally-induced synovitis.. Osteoarthritis Cartilage 1996 Jun;4(2):127-37.
    doi: 10.1016/S1063-4584(05)80321-8pubmed: 8806114google scholar: lookup
  56. Schu S, Nosov M, O'Flynn L, Shaw G, Treacy O, Barry F, Murphy M, O'Brien T, Ritter T. Immunogenicity of allogeneic mesenchymal stem cells.. J Cell Mol Med 2012 Sep;16(9):2094-103.
    doi: 10.1111/j.1582-4934.2011.01509.xpmc: PMC3822979pubmed: 22151542google scholar: lookup
  57. Barrachina L, Remacha AR, Romero A, Vázquez FJ, Albareda J, Prades M, Gosálvez J, Roy R, Zaragoza P, Martín-Burriel I, Rodellar C. Priming Equine Bone Marrow-Derived Mesenchymal Stem Cells with Proinflammatory Cytokines: Implications in Immunomodulation-Immunogenicity Balance, Cell Viability, and Differentiation Potential.. Stem Cells Dev 2017 Jan 1;26(1):15-24.
    doi: 10.1089/scd.2016.0209pubmed: 27712399google scholar: lookup
  58. Rani S, Ryan AE, Griffin MD, Ritter T. Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications.. Mol Ther 2015 May;23(5):812-823.
    doi: 10.1038/mt.2015.44pmc: PMC4427881pubmed: 25868399google scholar: lookup
  59. Hill JA, Cassano JM, Goodale MB, Fortier LA. Antigenicity of mesenchymal stem cells in an inflamed joint environment.. Am J Vet Res 2017 Jul;78(7):867-875.
    doi: 10.2460/ajvr.78.7.867pubmed: 28650243google scholar: lookup
  60. Ragni E, Perucca Orfei C, De Luca P, Mondadori C, Viganò M, Colombini A, de Girolamo L. Inflammatory priming enhances mesenchymal stromal cell secretome potential as a clinical product for regenerative medicine approaches through secreted factors and EV-miRNAs: the example of joint disease.. Stem Cell Res Ther 2020 Apr 28;11(1):165.
    doi: 10.1186/s13287-020-01677-9pmc: PMC7189600pubmed: 32345351google scholar: lookup
  61. van den Boom R, Brama PA, Kiers GH, DeGroot J, Barneveld A, van Weeren RR. The influence of repeated arthrocentesis and exercise on matrix metalloproteinase and tumour necrosis factor alpha activities in normal equine joints.. Equine Vet J 2004 Mar;36(2):155-9.
    doi: 10.2746/0425164044868602pubmed: 15038439google scholar: lookup
  62. Tulamo RM, Bramlage LR, Gabel AA. Sequential clinical and synovial fluid changes associated with acute infectious arthritis in the horse.. Equine Vet J 1989 Sep;21(5):325-31.
    doi: 10.1111/j.2042-3306.1989.tb02681.xpubmed: 2776718google scholar: lookup
  63. Lucia JL, Coverdale JA, Arnold CE, Winsco KN. Influence of an intra-articular lipopolysaccharide challenge on markers of inflammation and cartilage metabolism in young horses.. J Anim Sci 2013 Jun;91(6):2693-9.
    doi: 10.2527/jas.2012-5981pubmed: 23508023google scholar: lookup
  64. Wang G, Li X, Jiang R, Li Y, Fan X, Zheng Y. Changes in synovial fluid inflammatory mediators and cartilage biomarkers after experimental acute equine synovitis. Bull Vet Inst Pulawy (2015) 59:129–34.
    doi: 10.1515/bvip-2015-0019google scholar: lookup

Citations

This article has been cited 10 times.
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.